https://www.biospace.com/drug-development/abb...ps-growing
Meanwhile, smaller biotechs like Compass Pathways and Definium are waiting in the wings with their own psychedelics. Compass has multiple Phase 3 readouts planned this year for its psilocybin-based therapy for treat-resistant depression, COMP360, while Definium—formerly MindMed—will drop three Phase 3 datasets for its LSD-based drug DT120 for generalized anxiety disorder and MDD. Both companies are likely to apply for FDA approval before the end of this year, Wainwright analyst Patrick Trucchio told BioSpace last month.
“So by 2027, that’s a reality that DT120 and COMP360 are probably going to be approved,” he predicted.